ArticleMilitary Medical Research2025
Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study.
Article in Military Medical Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- HHV-7 encephalitis following allogeneic hematopoietic stem cell transplantation: A case report and literature review.Cell transplantationPooled it
- Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.Signal transduction and targeted therapy · 2026Trial
- Article
- Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Current status, development and challenges in the treatment of chronic graft-versus-host disease.Medical review (2021) · 2026Article
- Ultra-Low BCR::ABL1 positivity by digital PCR does not improve post-transplant risk stratification beyond real-time PCR in Ph+ acute lymphoblastic leukemia post-transplant.Clinical and experimental medicine · 2026Observational
- Alternative donors, particularly haploidentical donors, are safe and effective for elderly patients with adverse-risk AML: a multicenter TROPHY study.Blood cancer journal · 2026Article
- Letermovir for cytomegalovirus prophylaxis after allogeneic hematopoietic stem cell transplantation in acute leukemia patients: results of the LETreal study.Frontiers in immunology · 2026Article
- Evaluation of cyclophosphamide for steroid-refractory hepatic acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment.Frontiers in immunology · 2026Review
- Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Hematology specialist nurse-led continuity-of-care for high-risk hematopoietic cell transplantation recipients.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Xenopax is effective for the treatment and prophylaxis of acute graft-versus-host disease.Blood science (Baltimore, Md.) · 2025Article
- Clinical manifestations and outcomes of EBV-related secondary hemophagocytic lymphohistiocytosis.Annals of hematology · 2025Article
- High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Gut microbiota and acute graft-versus-host disease.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Xenopax from a real-world and economic perspective: The future of second-line treatment and prophylaxis for SR-aGVHD.Cell transplantationReview
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteroid-refractory (SR) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Xenopax, a novel and the only available humanized interleukin-2 (IL-2) receptor antagonist, has been approved as a category 2 biological product by the National Medical Products Administration. This study aims to evaluate the efficacy, safety, and prognostic factors of xenopax treatment for SR-aGVHD in real-world settings.
methodsThis was a multicenter, retrospective analysis that included SR-aGVHD patients who received xenopax at 17 hospitals across China. The data were collected from the electronic medical records in transplant databases. The primary endpoint was the 28-day overall response rate (ORR), encompassing both partial and complete responses. This study also included independent historical SR-aGVHD cohorts treated with best available treatments (BATs, n = 1009) as controls.
resultsIn total, 172 SR-aGVHD patients were included in this study. Xenopax was administered either as monotherapy (n = 60) or in combination with other second-line treatments (n = 112). The ORR was 64.5% [95% confidence interval (CI) 57.3-71.7%] on day 28 and 82.6% (95% CI 76.9-88.3%) at any time after xenopax treatment. The 2-year probabilities of disease-free survival, overall survival, non-relapse mortality (NRM), and relapse after xenopax treatment were 57.0% (95% CI 49.9-65.0%), 68.0% (95% CI 61.4-75.4%), 24.2% (95% CI 18.0-30.9%), and 19.0% (95% CI 12.8-25.2%), respectively. The ORR and survival were similar between patients with and without prior second-line treatments. The conditioning regimen and human leukocyte antigen disparity did not impact the efficacy of xenopax treatment. According to the multivariate analysis, the presence of grade III-IV aGVHD did not adversely affect the therapeutic response or survival. Xenopax also showed some superiority over BATs in historical cohorts.
conclusionsOur real-world findings suggest that xenopax is an effective and safe treatment for SR-aGVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.